Floatz logo

Ipatasertib

Carcinoma Of Esophagus

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

40 Active assets in the Carcinoma Of Esophagus cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
Sapanisertib
National Cancer Institute (NCI)
Phase 2CCC
Defactinib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Ipatasertib is also rated in:

estrogen-receptor positive breast cancerActive
BB
Indicative · Phase 2
64 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
60 / 100
View asset →
metastatic prostate carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →